Lantern Pharma Inc. (LTRN): who owns it and who trades it
As of Nov 16, 2026, LTRN insiders reported 1 purchase worth $100K in the last 12 months. The largest buyer was Lee Troy Schalop (Director), with $100K. 1 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Lantern Pharma
From the latest filingsOverall: more buying than selling. Insiders and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns LTRN
39 funds and institutions reported LTRN shares worth $12M at the end of Q2 2026, about 26% of the company. The largest holder is Empery Asset Management, LP with 7.5%.
Funds and institutions (13F) 26%Everyone else 74%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Empery Asset Management, LP | 842,669 | 7.49% | $3.5M | – |
| CM Management, LLC | 500,000 | 4.44% | $2.1M | – |
| Vanguard Capital Management LLC | 425,118 | 3.78% | $1.8M | – |
| Renaissance Technologies LLC | 291,039 | 2.59% | $1.2M | – |
| BIOS Capital Management, LP | 249,397 | 2.22% | $1M | – |
| Geode Capital Management, LLC | 102,819 | 0.91% | $429K | – |
| Vanguard Fiduciary Trust Co | 49,950 | 0.44% | $208K | – |
| Citadel Advisors LLC | 47,895 | 0.43% | $200K | – |
| Westside Investment Management, Inc. | 47,850 | 0.43% | $200K | – |
| Quadrature Capital Ltd | 39,593 | 0.35% | $165K | – |
| NewEdge Advisors, LLC | 27,049 | 0.24% | $113K | – |
| Horizon Kinetics Asset Management LLC | 25,164 | 0.22% | $105K | – |
| DAVENPORT & Co LLC | 23,814 | 0.21% | $99.3K | – |
| State Street Corp | 23,652 | 0.21% | $98.6K | – |
| BlackRock, Inc. | 22,350 | 0.20% | $93.2K | – |
| Bank of New York Mellon Corp | 21,301 | 0.19% | $88.8K | – |
| Northern Trust Corp | 17,485 | 0.16% | $72.9K | – |
| XTX Topco Ltd | 17,415 | 0.15% | $72.6K | – |
| Dimensional Fund Advisors LP | 16,725 | 0.15% | $69.7K | – |
| UBS Group AG | 16,632 | 0.15% | $69.4K | – |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, LTRN insiders reported $100K of open-market purchases and $0 of sales.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| May 12, 2026 | Lee Troy Schalop | Director | Purchase | 48,544 | $2.06 | $100K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Lee Troy Schalop | Director | $100K | – | May 12, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
LTRN short interest
Moderate short interest. 7.2% of LTRN shares are sold short: about 1 share in 14. Over the last 12 reports the number of shares short went down 51%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 924,479 LTRN shares were sold short, 7.2% of the shares outstanding, up 137.9% from the report before. At the average daily volume of 345,314 shares, buying them all back would take about 2.7 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 924,479 | 7.23% | +138% | 345,314 | 2.7 |
| Oct 15, 2026 | 388,655 | 3.04% | -20% | 259,330 | 1.5 |
| Sep 30, 2026 | 485,750 | 3.80% | -13% | 369,538 | 1.3 |
| Sep 15, 2026 | 557,981 | 4.36% | -1% | 167,376 | 3.3 |
| Aug 31, 2026 | 564,632 | 4.42% | -19% | 135,718 | 4.2 |
| Aug 14, 2026 | 693,034 | 5.42% | -18% | 85,784 | 8.1 |
| Jul 31, 2026 | 846,372 | 7.52% | -10% | 83,917 | 10.1 |
| Jul 15, 2026 | 945,216 | 8.40% | +2% | 184,384 | 5.1 |
| Jun 30, 2026 | 929,051 | 8.25% | -32% | 179,613 | 5.2 |
| Jun 15, 2026 | 1.37M | 12.16% | -7% | 230,415 | 5.9 |
| May 29, 2026 | 1.48M | 13.13% | -22% | 256,896 | 5.8 |
| May 15, 2026 | 1.90M | 16.90% | -6% | 355,731 | 5.3 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Lantern Pharma company events
Lantern Pharma filed 12 reports on Form 8-K in the last 12 months, 1 of them about an important change (listing). The latest was on Oct 1, 2026.
- Oct 1, 2026ListingLantern Pharma Inc. received notice from The Nasdaq Stock Market LLC that the Company is not in compliance with Nasdaq’s Listing Rule 5550(b)(2), as the market value of listed securities for the Company’s common stock had been below the minimum MVLS Requirement of $35 million for the last 30… Filing
- Sep 30, 2026AgreementLantern Pharma Inc. entered into a securities purchase agreement with an institutional investor, pursuant to which the Company agreed to issue and sell to such investor in a registered direct offering (i) 1,469,725 shares of common stock, par value $0.0001 per share, of the Company, at an offering… Filing
- Sep 24, 2026AnnouncementShared information with investors. Filing
- Sep 23, 2026AnnouncementShared information with investors. Filing
- Aug 14, 2026ResultsReleased financial results. Filing
- Aug 3, 2026AnnouncementShared information with investors. Filing
- Jun 2, 2026AnnouncementShared information with investors. Filing
- May 15, 2026ResultsReleased financial results. Filing
- May 14, 2026AgreementLantern Pharma Inc. entered into a securities purchase agreement with institutional investors, pursuant to which the Company agreed to issue and sell to such investors in a registered direct offering (i) 1,454,175 shares of common stock, par value $0.0001 per share, of the Company, at an offering… Filing
- Apr 10, 2026AnnouncementShared information with investors. Filing
- Mar 30, 2026ResultsReleased financial results. Filing
- Jan 23, 2026AnnouncementShared information with investors. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Lantern Pharma financials
Famous investors that hold LTRN
1 of the 50 well-known investors we track reported holding LTRN in their latest 13F filing. The largest position is Jim Simons's, worth $372K.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 368,407 | $372K | 0.0% | +27% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named LTRN in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Armistice Capital, LLC | 13G | 10.0% |
| Nov 16, 2026 | Armistice Capital, LLC | 13G | 10.0% |
| Oct 13, 2026 | Empery Asset Management, LP | 13G/A | 5.0% |
| Oct 13, 2026 | Empery Asset Management, LP | 13G/A | 5.0% |
Questions about Lantern Pharma Inc. (LTRN) stock
Who owns the most LTRN stock?
The largest reported owner of Lantern Pharma Inc. (LTRN) is Empery Asset Management, LP, with 7.5% of the company. In total, 39 funds and institutions reported holding LTRN at the end of Q2 2026, together about 26% of the shares. See the largest owners.
Are LTRN insiders buying or selling?
In the last 12 months, LTRN insiders reported 1 open-market purchase worth $100K and no sales. The latest trade was on May 12, 2026. See every trade.
What is the short interest in LTRN?
As of Oct 30, 2026, 924,479 LTRN shares were sold short, 7.2% of the shares outstanding, up 137.9% from the report before. At the average daily volume of 345,314 shares, buying them all back would take about 2.7 trading days (days to cover). See the history.
Which famous investors hold LTRN?
1 of the 50 well-known investors we track reported LTRN in their latest 13F filing, including Jim Simons. The largest position is worth $372K. See all holders.
Executive pay
Lantern Pharma's chief executive was paid a total of $764K for the year ended Dec 31, 2025, down 30% from $1.1M the year before. In the last 12 months, Lantern Pharma's executives and directors bought $100K of stock on the open market and sold none.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.